Zevra Therapeutics (ZVRA) Non Operating Income (2014 - 2026)

Zevra Therapeutics has reported Non Operating Income for 13 years, with the latest figure at -$7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 313.12% year-over-year to -$7.3 million; the trailing twelve-month figure through Mar 2026 stood at $138.8 million (up 4082.62% YoY), and the FY2025 full-year result was $149.6 million, up 4869.56% from the prior year.
• Non Operating Income for Q1 2026 stood at -$7.3 million, down from $3.4 million in the prior quarter.
• The five-year high for Non Operating Income was $147.9 million in Q2 2025, with the low at -$7.3 million in Q1 2026.
• Historically, Non Operating Income has averaged $8.6 million across 5 years, with a median of $2.9 million in 2022.
• Annual changes were most pronounced in 2023 — Non Operating Income plunged 5333.33% — and 2025, when it surged 3654.95%.
• Zevra Therapeutics' Non Operating Income stood at $6.1 million in 2022, then tumbled by 177.45% to -$4.7 million in 2023, then declined by 4.58% to -$5.0 million in 2024, then surged by 167.67% to $3.4 million in 2025, then plunged by 319.1% to -$7.3 million in 2026.
• The last three Non Operating Income figures came in at -$7.3 million (Q1 2026), $3.4 million (Q4 2025), and -$5.1 million (Q3 2025), per Business Quant data.